Diagnosis and treatment of hypogonadism in men

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 25, Issue 2, 2011, Pages 251-270

  Bhasin, Shalender ^a,b   Basaria, Shehzad ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

adverse effects of testosterosterone therapy; androgen deficiency; androgen formulations; hypogonadism; late onset hypogonadism; testosterone and cardiovascular risk; testosterone replacement; testosterone therapy

Indexed keywords

17 ALPHA METHY TESTOSTERONE; 7 ALPHA METHYL 19 NORTESTOSTERONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ACNE; AGE; ANDROGEN THERAPY; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG COST; DRUG FORMULATION; DRUG PELLET; ERYTHROCYTOSIS; GERIATRIC PATIENT; GYNECOMASTIA; HEALTH CARE COST; HEART INFARCTION; HEREDITY; HUMAN; HYPOGONADISM; HYPOPHYSIS DISEASE; HYPOTHALAMUS DISEASE; LEG EDEMA; LIVER TOXICITY; MALE INFERTILITY; MALE TYPE ALOPECIA; OILY SKIN; PATIENT MONITORING; PATIENT PREFERENCE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; TESTIS DISEASE; TESTOSTERONE BLOOD LEVEL; TREATMENT CONTRAINDICATION; URINARY TRACT DISEASE;

CARDIOVASCULAR DISEASES; HUMANS; HYPOGONADISM; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 79952558575     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2010.12.002     Document Type: Review

References (123)

1. Bhasin S, Cunningham GR, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2010; 95: 2536-2559.
2. Bhasin S. Testicular disorders. In Larsen PR, Kronenberg HM, Melmed S & Polanski KS (eds.). Williams' Textbook of Endocrinology. 11th ed. Philadelphia, PA: Elsevier, 2008.
3. Harman SM, Metter EJ, Tobin JD et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. Journal of Clinical Endocrinology & Metabolism 2001; 86: 724-731. (Pubitemid 32207487)
4. Wu FC, Tajar A, Beynon JM, et alEMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. The New England Journal of Medicine 2010; 363(2): 123-135.
5. Orwoll ES, Nielson CM, Labrie F, et alOsteoporotic fractures in men (MrOS) research group. Evidence for geographical and racial variation in serum sex steroid levels in older men. Journal of Clinical Endocrinology & Metabolism 2010; 95: E151-E160.
6. Krasnoff JB, Basaria S, Pencina MJ et al. Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the framingham offspring study. Journal of Clinical Endocrinology & Metabolism 2010.
7. Mulligan T, Frick MF, Zuraw QC et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International Journal of Clinical Practice 2006; 60: 762-769. (Pubitemid 43881152)
8. Araujo AB, Esche GR, Kupelian V et al. Prevalence of symptomatic androgen deficiency in men. Journal of Clinical Endocrinology & Metabolism 2007; 92: 4241-4247. (Pubitemid 350074738)
9. Zitzmann M, Faber S & Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. Journal of Clinical Endocrinology & Metabolism 2006; 91: 4335-4343. (Pubitemid 44833407)
10. Hall SA, Esche GR, Araujo AB et al. Correlates of low testosterone and symptomatic androgen deficiency in a population- based sample. Journal of Clinical Endocrinology & Metabolism 2008; 93: 3870-3877.
11. Buena F, Swerdloff RS, Steiner BS et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 1993 May; 59(5): 1118-1123. (Pubitemid 23139689)
12. Kelleher S, Conway AJ & Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. Journal of Clinical Endocrinology & Metabolism 2004; 89: 3813-3817. (Pubitemid 39071477)
13. Travison TG, Araujo AB, O'Donnell AB et al. A population-level decline in serum testosterone levels in American men. Journal of Clinical Endocrinology & Metabolism 2007; 92: 196-202. (Pubitemid 46075010)
14. Andersson AM, Jensen TK, Juul A et al. Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. Journal of Clinical Endocrinology & Metabolism 2007; 92: 4696-4705. (Pubitemid 350223446)
15. Bhasin S, Zhang A, Coviello A et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008; 73: 1311-1317.
16. Rosner W, Auchus RJ, Azziz R et al. Utility, limitations and pitfalls in measuring testosterone: An Endocrine Society Position Statement. Journal of Clinical Endocrinology & Metabolism 2007; 92: 405-413.
17. Rosner W, Vesper H; Endocrine Society; American Association for Clinical Chemistry; American Association of Clinical Endocrinologists; Androgen Excess/PCOS Society; American Society for Bone and Mineral Research; American Society for Reproductive Medicine; American Urological Association; Association of Public Health Laboratories; Endocrine Society; Laboratory Corporation of America; North American Menopause Society; Pediatric Endocrine Society. Toward excellence in testosterone testing: a consensus statement. Journal of Clinical Endocrinology & Metabolism. 2010;95: 4542-4548.
18. Wang C, Catlin DH, Demers LM et al. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. Journal of Clinical Endocrinology & Metabolism 2004; 89: 534-543. (Pubitemid 38269854)
19. Bremner WJ, Vitiello MV & Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. Journal of Clinical Endocrinology & Metabolism 1983; 56: 1278-1281. (Pubitemid 13055125)
20. Brambilla DJ, O'Donnell AB, Matsumoto AM et al. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clinical Endocrinology (Oxford) 2007; 67: 853-862. (Pubitemid 350135128)
21. Rosner W. Sex steroids and the free hormone hypothesis. Cell 2006; 124: 455-456. author reply 456-457.
22. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology & Metabolism 1999; 84: 3666-3672. (Pubitemid 30645223)
23. Manni A, Pardridge WM, Cefalu Wet al. Bioavailability of albumin-bound testosterone. Journal of Clinical Endocrinology & Metabolism 1985; 61: 705-771.
24. Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: with illustrative examples from male and female populations. Steroids 2009; 74: 512-519.
25. Winters SJ, Kelley DE & Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? Clinical Chemistry 1998; 44: 2178-2182.
26. Handelsman DJ & Liu PY. Klinefelter's syndrome-a microcosm of male reproductive health. Journal of Clinical Endocrinology & Metabolism 2006; 91: 1220-1222.
27. Citron JT, Ettinger B, Rubinoff H et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. Journal of Urology 1996; 155: 529-533. (Pubitemid 26023538)
28. Buvat J & Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. Journal of Urology 1997; 158: 1764-1767. (Pubitemid 27433148)
29. Morley JE, Charlton E, Patrick P et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-1242.
30. Smith KW, Feldman HA & McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clinical Endocrinology (Oxford) 2000; 53: 703-711. (Pubitemid 32096681)
31. Moore C, Huebler D, Zimmermann T et al. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. European Urology 2004; 46: 80-87. (Pubitemid 38748514)
32. Stanley HL, Schmitt BP, Poses RM et al. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? Journal of the American Geriatrics Society 1991; 39: 766-771.
33. Cauley JA, Ewing SK, Taylor BC, et alOsteoporotic fractures in men study (MrOS) research group. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density-the osteoporotic fractures in men study. Journal of Clinical Endocrinology & Metabolism 2010; 95: 4314-4323.
34. Riggs BL, Khosla S & Melton 3rd LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews 2002; 23: 279-302.
35. Dobs AS, Few 3rd WL, Blackman MR et al. Serum hormones in men with human immunodeficiency virus-associated wasting. Journal of Clinical Endocrinology & Metabolism 1996; 81: 4108-4112. (Pubitemid 26380425)
36. Arver S, Sinha-Hikim I, Beall G et al. Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss. Journal of Andrology 1999; 20: 611-618. (Pubitemid 29453578)
37. Singh AB, Norris K, Modi N et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. Journal of Clinical Endocrinology & Metabolism 2001; 86: 2437-2445. (Pubitemid 32545688)
38. Creutzberg EC & Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. European Respiratory Journal-Supplement 2003; 46: 76s-80s.
39. Dhindsa S, Prabhakar S, Sethi M et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. Journal of Clinical Endocrinology & Metabolism 2004; 89: 5462-5468. (Pubitemid 39518427)
40. Reid IR, Ibbertson HK, France JT et al. Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. British Medical Journal (Clinical Research Edition) 1985; 291: 574. (Pubitemid 15225461)
41. Wahlstrom JT, Tang A, Cofrancesco J et al. Gonadal hormone levels in injection drug users. Drug and Alcohol Dependence 2000; 60: 311-313.
42. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. Journal of Pain 2002; 5: 377-384. (Pubitemid 35176459)
43. Bhasin S, Enzlin P, Coviello A et al. Sexual dysfunction in men and women with endocrine disorders. Lancet 2007 Feb 17; 369(9561): 597-611.
44. Arver S, Dobs AS, Meikle AWet al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. Journal of Urology 1996; 155: 1604-1608. (Pubitemid 26126959)
45. Steidle C, Schwartz S, Jacoby K et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. Journal of Clinical Endocrinology & Metabolism 2003; 88: 2673-2681. (Pubitemid 36724441)
46. Kwan M, Greenleaf WJ, Mann J et al. The nature of androgen action on male sexuality: a combined laboratory-selfreport study on hypogonadal men. Journal of Clinical Endocrinology & Metabolism 1983; 57: 557-562.
47. Snyder PJ, Peachey H, Berlin JA et al. Effects of testosterone replacement in hypogonadal men. Journal of Clinical Endocrinology & Metabolism 2000 Aug; 85(8): 2670-2677. (Pubitemid 32269134)
48. Alexander GM & Sherwin BB. The association between testosterone, sexual arousal, and selective attention for erotic stimuli in men. Hormones and Behaviour 1991; 25: 367-381.
49. Cunningham GR, Hirshkowitz M, Korenman SG et al. Testosterone replacement therapy and sleep-related erections in hypogonadal men. Journal of Clinical Endocrinology & Metabolism 1990; 70: 792-797.
50. Wang C, Alexander G, Berman N et al. Testosterone replacement therapy improves mood in hypogonadal men-a clinical research center study. Journal of Clinical Endocrinology & Metabolism 1996; 81: 3578-3583. (Pubitemid 26339918)
51. Janowsky JS, Oviatt SK & Orwoll ES. Testosterone influences spatial cognition in older men. Behavioral Neuroscience 1994; 108: 325-332. (Pubitemid 24142694)
52. Cherrier MM, Asthana S, Plymate S et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001; 57: 80-88. (Pubitemid 32634854)
53. Marin P, Holmang S, Jonsson L et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. International Journal of Obesity Related Metabolic Disorder 1992; 16: 991-997. (Pubitemid 23010023)
54. Singh AB, Hsia S, Alaupovic P et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Journal of Clinical Endocrinology & Metabolism 2002; 87: 136-143. (Pubitemid 34084682)
55. Pitteloud N, Mootha VK, Dwyer AA et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28(7): 1636-1642. (Pubitemid 41340902)
56. Kapoor D, Goodwin E, Channer KS et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2006; 154: 899-906. (Pubitemid 43997730)
57. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. Journal of the American Medical Association 2008; 299: 39-52.
58. Basu R, Dalla Man C, Campioni M et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 2007; 30: 1972-1978. (Pubitemid 47219403)
59. Bhasin S, Calof O, Storer TWet al. Drug insights: anabolic applications of testosterone and selective androgen receptor modulators in aging and chronic illness. Nature Clinical Practice Endocrinology & Metabolism 2006; 2: 133-140.
60. Fowler Jr. JE & Whitmore Jr. WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. The Journal of Urology 1981; 126: 372-375. (Pubitemid 11061000)
61. Bhasin S, Singh AB, Mac RP et al. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. Journal of Andrology 2003; 24: 299-311.
62. Agarwal PK & Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. The Journal of Urology 2005; 173: 533-536.
63. Kaufman JM & Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. The Journal of Urology 2004; 172: 920-922. (Pubitemid 39096423)
64. Khera M, Grober ED, Najari B et al. Testosterone replacement therapy following radical prostatectomy. The Journal of Sexual Medicine 2009; 6: 1165-1170.
65. Snyder PJ & Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. Journal of Clinical Endocrinology & Metabolism 1980; 51: 1335-1339.
66. Sokol RZ, Palacios A, Campfield LA et al. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertility and Sterility 1982; 37: 425-430. (Pubitemid 12183703)
67. Wang C, Berman N, Longstreth JA et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. Journal of Clinical Endocrinology & Metabolism 2000; 85: 964-969. (Pubitemid 32269334)
68. Dobs AS, Meikle AW, Arver S et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Journal of Clinical Endocrinology & Metabolism 1999; 84: 3469-3478. (Pubitemid 30645193)
69. Arver S, Dobs AS, Meikle AW et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clinical Endocrinology (Oxford) 1997; 47: 727-737. (Pubitemid 28046562)
70. Wang C, Swerdloff R, Kipnes M et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. Journal of Clinical Endocrinology & Metabolism 2004; 89: 3821-3829. (Pubitemid 39071479)
71. Handelsman DJ, Conway AJ & Boylan LM. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. Journal of Clinical Endocrinology & Metabolism 1990; 71: 216-222.
72. Skakkebaek NE, Bancroft J, Davidson DW et al. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clinical Endocrinology (Oxford) 1981; 14: 49-61. (Pubitemid 11051031)
73. Schubert M, Minnemann T, Hubler D et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. Journal of Clinical Endocrinology & Metabolism 2004; 89: 5429-5434. (Pubitemid 39518421)
74. Bhasin S, Swerdloff RS, Steiner B et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. Journal of Clinical Endocrinology & Metabolism 1992; 74: 75-83.
75. Amory JK, Anawalt BD, Blaskovich PD et al. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. Journal of Andrology 2003; 23: 84-91. (Pubitemid 34001133)
76. Behre HM & Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. Journal of Clinical Endocrinology & Metabolism 1992; 75: 1204-1210.
77. Anderson RA, Wallace AM, Sattar N et al. Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19- nortestosterone in hypogonadal men. Journal of Clinical Endocrinology & Metabolism 2003; 88: 2784-2793. (Pubitemid 36724456)
78. Bhasin S & Jasuja R. Selective androgen receptor modulators as function promoting therapies. Current Opinion in Clinical Nutrition and Metabolic Care 2009; 12(3): 232-234.
79. Calof O, Singh AB, Lee ML et al. Adverse events associated with testosterone supplementation of older men. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2005; 60: 1451-1457.
80. Fernández-Balsells HM, Murad MH, Melanie L et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism 2009.
81. Haddad RM, Kennedy CC, Caples SM et al. Testosterone and cardiovascular risk in men: a systematic review and metaanalysis of randomized placebo-controlled trials. Mayo Clinic Proceedings 2007; 82: 29-39. (Pubitemid 46036319)
82. Bachman E, Feng R, Travison T et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosteroneinduced erythrocytosis. Journal of Clinical Endocrinology & Metabolism 2010; 95(10): 4743-4747.
83. Coviello AD, Kaplan B, Lakshman KM et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology & Metabolism 2008 Mar; 93(3): 914-919. (Pubitemid 351398573)
84. Matsumoto AM, Sandblom RE, Schoene RB et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clinical Endocrinology (Oxford) 1985; 22: 713-721. (Pubitemid 15046172)
85. Behre HM, Bohmeyer J & Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clinical Endocrinology (Oxford) 1994; 40: 341-349. (Pubitemid 24194627)
86. Alexandersen P, Haarbo J & Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125: 1-13. (Pubitemid 26267117)
87. Liu PY, Death AK & Handelsman DJ. Androgens and cardiovascular disease. Endocrine Reviews 2003; 24: 313-340. (Pubitemid 36724373)
88. Basaria S, Coviello A, Travison T et al. Adverse events associated with testosterone administration. The New England Journal of Medicine 2010; 363: 109-122.
89. Zmuda JM, Cauley JA, Kriska A et al. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former multiple risk factor intervention trial participants. The American Journal of Epidemiology 1997; 146: 609-617. (Pubitemid 27454548)
90. Barrett-Connor E & Khaw KT. Endogenous sex hormones and cardiovascular disease in men. A prospective populationbased study. Circulation 1988; 78: 539-545.
91. Lakshman KM, Bhasin S & Araujo AB. Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2010 May; 65(5): 503.
92. Laughlin GA, Barrett-Connor E & Bergstrom J. Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology & Metabolism 2008 Jan; 93(1): 68-75.
93. Tivesten A, Vandenput L, Labrie F et al. Low serum testosterone and estradiol predict mortality in elderly men. Journal of Clinical Endocrinology & Metabolism 2009 Jul; 94(7): 2482-2488.
94. Whitsel EA, Boyko EJ, Matsumoto AM et al. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. American Journal of Medicine 2001; 111: 261-269. (Pubitemid 32885620)
95. Holmäng A & Björntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiologica Scandinavica 1992 Dec; 146(4): 505-510. (Pubitemid 23008349)
96. English KM, Steeds RP, Jones TH et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-1911.
97. 2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology 2006; 147: 2675-2680.
98. Huggins C & Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Journal of Urology 2002; 168: 9-12.
99. Morgentaler A, Bruning 3rd CO & DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. Journal of the American Medical Association 1996; 276: 1904-1906. (Pubitemid 26419188)
100. Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. Journal of Clinical Endocrinology & Metabolism 2004; 89: 503-510. (Pubitemid 38269849)
101. Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. Journal of Clinical Endocrinology & Metabolism 1999; 84. 2647-265.
102. Riehmann M, Rhodes PR, Cook TD et al. Analysis of variation in prostate-specific antigen values. Urology 1993; 42: 390-397. (Pubitemid 23314330)
103. Gormley GJ, Stoner E, Bruskewitz RC, et alThe Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. The New England Journal of Medicine 1992; 327: 1185-1191.
104. Carter HB. PSA variability versus velocity. Urology 1997; 49: 305.
105. Gray A, Berlin JA, McKinlay JB et al. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. The Journal of Clinical Epidemiology 1991; 44: 671-684.
106. Morley JE, Kaiser FE, Perry 3rd HM et al. Longitudinal changes in testosterone, luteinizing hormone, and folliclestimulating hormone in healthy older men. Metabolism 1997; 46: 410-413. (Pubitemid 27172090)
107. Ferrini RL & Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. The American Journal of Epidemiology 1998; 147: 750-754. (Pubitemid 28183274)
108. Mohr BA, Bhasin S, Link CL et al. Do changes in adiposity over a 9 year period predict testosterone levels in older men? Longitudinal results from the massachusetts male aging study. European Journal of Endocrinology 2006.
109. Roy TA, Blackman MR, Harman SM et al. Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. American Journal of Physiology - Endocrinology and Metabolism 2002; 283: E284-E294. (Pubitemid 34827443)
110. Baumgartner RN, Waters DL, Gallagher D et al. Predictors of skeletal muscle mass in elderly men and women. Mechanisms of Ageing and Development 1999; 107: 123-136. (Pubitemid 29138849)
111. O'Donnell AB, Travison TG, Harris SS et al. Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the massachusetts male aging study. Journal of Clinical Endocrinology & Metabolism 2006; 91: 425-431. (Pubitemid 43236905)
112. Travison TG, Morley JE, Araujo AB et al. The relationship between libido and testosterone levels in aging men. Journal of Clinical Endocrinology & Metabolism 2006; 91: 2509-2513. (Pubitemid 44024610)
113. Araujo AB, Durante R, Feldman HA et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the massachusetts male aging study. Psychosomatic Medicine 1998; 60: 458-465. (Pubitemid 28354846)
114. Page ST, Amory JK, Bowman FD et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. Journal of Clinical Endocrinology & Metabolism 2004; 90: 1502-1510.
115. Kenny AM, Prestwood KM, Gruman CA et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2001; 56: M266-M272. (Pubitemid 32381803)
116. Nair KS, Rizza RA, O'Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. The New England Journal of Medicine 2006; 355: 1647-1659. (Pubitemid 44583955)
117. Wittert GA, Chapman IM, Haren MT et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2003; 58: 618-625. (Pubitemid 36900168)
118. Blackman MR, Sorkin JD, Munzer T et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. The Journal of the American Medical Association 2002; 288: 2282-2292. (Pubitemid 35291758)
119. Sattler F, Bhasin S, He J et al. Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2010 Nov 8.
120. Srinivas-Shankar U, Roberts SA, Connolly MJ et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. Journal of Clinical Endocrinology & Metabolism 2010; 95: 639-650.
121. Ferrando AA, Sheffield-Moore M, Yeckel CW et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. American Journal of Physiology - Endocrinology and Metabolism 2002; 282: E601-E607. (Pubitemid 34654776)
122. Marks LS, Mazer NA, Mostaghel E et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. The Journal of the American Medical Association 2006; 296: 2351-2361.
123. Liverman CT & Blazer DG. Testosterone and aging, clinical research directions. Washington, D.C: National Academies Press, 2004.